시장보고서
상품코드
1642913

요로감염 검사 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 부문, 유형별, 최종 용도별, 지역별, 경쟁(2026-2030년)

Urinary Tract Infection Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End use, By Region and Competition, 2026-2030F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 180 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

요로감염 검사 세계 시장 규모는 2024년 6억 1,085만 달러로 평가되었고, 2030년까지 예측 기간 동안 4.20%의 연평균 복합 성장률(CAGR)로 꾸준히 성장할 것으로 예상됩니다.

요로감염(UTI)은 세계적으로 수백만 명이 앓고 있는 흔한 질병으로 경제적, 의료적으로 큰 부담이 되고 있습니다. 효과적인 치료와 환자 관리를 위해서는 정확하고 신속한 진단이 필수적입니다. 이러한 필요성이 세계 요로감염 검사 시장의 성장을 주도하고 있습니다. 요로 감염은 유해한 박테리아가 비뇨기 계통에 침입해 증식하면서 발생하며, 배뇨 시 통증과 불편함, 빈뇨, 발열 등 다양한 증상을 유발할 수 있습니다. 요로결석은 방광, 요도, 신장 등 비뇨기 계통의 모든 부위에 영향을 미칠 수 있습니다. 요로 결석의 신속하고 정확한 진단은 일반적으로 항생제를 포함한 적절한 치료 요법을 결정하는 데 필수적입니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 6억 1,085만 달러
시장 규모 : 2030년 7억 8,372만 달러
CAGR : 2025-2030년 4.20%
급성장 부문 방광염
최대 시장 북미

세계 요로감염 검사 시장은 요로결석 유병률 증가, 환자 및 의료 전문가들의 인식 증가, 진단 검사 기술 발전 등 다양한 요인으로 인해 최근 몇 년동안 괄목할 만한 성장세를 보이고 있습니다. 시장 규모는 상당한 규모에 달할 것으로 예상되며, 향후 몇 년동안 안정적인 성장이 예상되며, 코로나19 사태로 인해 신속 진단 검사의 중요성이 부각되면서 요로결석 검사에 대한 수요가 더욱 증가하고 있습니다.

요로감염 검사 시장의 중요한 트렌드 중 하나가 바로 현장 검사로의 전환입니다. 현장 검사는 빠른 결과를 제공하기 때문에 의료진이 신속하게 치료를 시작할 수 있도록 돕습니다. 핵산 증폭 검사 및 첨단 소변 분석기와 같은 진단 기술의 혁신으로 요로 결석 검사의 정확성과 효율성이 향상되고 있습니다. 요로결석 가정용 검사 키트는 환자가 집에서 자신의 건강 상태를 모니터링할 수 있는 편리함을 제공하면서 점점 더 널리 보급되고 있습니다. 이러한 추세는 코로나19 사태로 인해 사람들이 의료기관 방문을 최소화하려는 움직임으로 인해 더욱 탄력을 받고 있습니다. 신흥국에서는 헬스케어에 대한 인식과 인프라가 개선되고 있으며, 이는 해당 지역의 요로감염 검사 시장이 크게 성장하고 있습니다.

주요 시장 성장 촉진요인

요로감염증 발병률 증가가 세계 요로감염 검사 시장을 주도하고 있습니다.

민간 및 공공 부문의 투자 확대가 요로감염 검사 세계 시장을 주도하고 있습니다.

주요 시장 이슈

항생제 과다 사용

제한적인 인식

위양성 및 위음성

표준화 부족

비용 제약

새로운 기술

규제상의 장애물

원격의료와 원격검사

주요 시장 동향

기술의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 요로감염 검사 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별(요도염, 방광염, 신우신염)
    • 최종 용도별(일반 개업의(GP), 비뇨기과의, 비뇨기 부인과의, 병원 검사실, 참조 실험실, 기타)
    • 지역별
    • 기업별(2024)
  • 시장 맵
    • 유형별
    • 최종 용도별
    • 지역별

제5장 아시아태평양의 요로감염 검사 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 최종 용도별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 요로감염 검사 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 최종 용도별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 요로감염 검사 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 최종 용도별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 요로감염 검사 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 최종 용도별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 요로감염 검사 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 유형별
    • 최종 용도별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 인수합병(M&A)

제12장 세계의 요로감염 검사 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • QIAGEN NV
  • Accelerate Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.
  • BIOMERIEUX
  • T2 Biosystems, Inc.

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 25.02.27

Global Urinary Tract Infection Testing Market was valued at USD 610.85 Million in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.20% through 2030. Urinary tract infections (UTIs) are a common ailment affecting millions of individuals worldwide, with a substantial economic and healthcare burden. Accurate and timely diagnosis is crucial for effective treatment and patient care. This need has driven the growth of the global Urinary Tract Infection Testing Market. Urinary tract infections occur when harmful bacteria enter the urinary system and multiply, leading to various symptoms such as pain and discomfort during urination, frequent urges to urinate, and in some cases, fever. UTIs can affect any part of the urinary system, including the bladder, urethra, and kidneys. Rapid and accurate diagnosis of UTIs is essential to determine the appropriate treatment regimen, which typically involves antibiotics.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 610.85 Million
Market Size 2030USD 783.72 Million
CAGR 2025-20304.20%
Fastest Growing SegmentCystitis
Largest MarketNorth America

The global urinary tract infection testing market has witnessed significant growth in recent years, driven by various factors, including rising UTI incidence, increasing awareness among patients and healthcare professionals, and technological advancements in diagnostic tests. The market size is expected to reach a substantial figure, with projections suggesting steady growth in the coming years. The COVID-19 pandemic has also underscored the importance of rapid diagnostic testing, which has further contributed to the demand for UTI testing.

The shift towards point-of-care testing is a significant trend in the UTI testing market. Point-of-care tests provide quick results, enabling healthcare providers to initiate treatment promptly. Innovations in diagnostic technologies, such as nucleic acid amplification tests and advanced urine analyzers, have improved the accuracy and efficiency of UTI testing. Home testing kits for UTIs are becoming more popular, giving patients the convenience to monitor their health from the comfort of their homes. This trend has gained momentum due to the COVID-19 pandemic, as people seek to minimize healthcare facility visits. Developing countries are witnessing an increase in healthcare awareness and infrastructure, leading to substantial growth in UTI testing markets in these regions.

Key Market Drivers

Rising Urinary tract infections Incidence Rates is Driving the Global Urinary Tract Infection Testing Market

Urinary tract infections (UTIs) are one of the most common bacterial infections worldwide, affecting millions of people each year. Urinary tract infections (UTIs) represent the second most prevalent infectious disease worldwide, impacting over 150 million individuals each year. Uropathogenic Escherichia coli (UPEC), the primary etiological agent of UTIs, frequently forms biofilms that contribute to its persistence and resistance to antimicrobial treatments. This biofilm formation significantly complicates treatment strategies, as it enables UPEC to evade both the immune response and the action of antibiotics, further exacerbating the growing concern around antimicrobial resistance (AMR). While UTIs are typically not life-threatening, they can cause significant discomfort and inconvenience. Moreover, if left untreated, they can lead to more severe health complications. Recent years have seen a notable rise in UTI incidence rates, creating a demand for more efficient diagnostic tools and increasing the global Urinary Tract Infection Testing Market. Urinary tract infections (UTIs) represent a widespread health issue, impacting both quality of life and, in severe cases, overall mortality. Affecting approximately 1 in 10 men and more than half of all women during their lifetimes, UTIs target the kidneys, bladder, and urethra. If left untreated, these infections can escalate into sepsis, a life-threatening systemic condition. UTIs are responsible for an estimated 236,000 deaths annually worldwide, highlighting the critical need for effective treatments, early detection, and prevention strategies to mitigate the global health burden associated with these infections. UTIs are bacterial infections that can affect any part of the urinary system, including the bladder, urethra, and kidneys. The majority of UTIs are caused by Escherichia coli (E. coli) bacteria, but other bacteria can also be responsible. Common symptoms of UTIs include frequent urination, a burning sensation during urination, cloudy or bloody urine, and discomfort in the lower abdomen. Verse and misuse of antibiotics have led to the emergence of antibiotic-resistant strains of bacteria, making UTIs harder to treat. The rising prevalence of multidrug-resistant UTIs necessitates more accurate and prompt diagnosis. Modern lifestyles, such as increased sexual activity and the use of certain types of birth control, can contribute to an increased risk of UTIs. As the global population continues to age, older individuals become more susceptible to UTIs due to weakened immune systems and other age-related factors. Improved education and awareness regarding the symptoms and risks of UTIs may lead to more people seeking medical attention for these infections. In the elderly population, the most frequently reported urinary tract infections (UTIs) are cystitis, accounting for 37.6% of cases, followed by asymptomatic bacteriuria (ASB) at 31.9%. Pyelonephritis represents 13.9% of UTI cases, while urosepsis and prostatitis contribute to 10.2% and 6.4% of reported cases, respectively.

The demand for accurate and efficient UTI diagnostic tools has given rise to a thriving Urinary Tract Infection Testing Market. This market includes a wide range of products and services. Traditional urinalysis remains the most common method for diagnosing UTIs. However, advances in urinalysis techniques have allowed for more accurate and rapid results. Dipstick tests are cost-effective and easy-to-use tools for initial UTI screening. They can quickly detect key indicators of infection, such as nitrites and leukocytes. For complex or recurrent UTIs, microbiological culture tests are crucial for identifying the specific bacteria causing the infection and their antibiotic susceptibility. Advanced technology has made these tests more efficient and precise. Molecular testing methods, like polymerase chain reaction (PCR), can detect UTIs with high sensitivity and specificity. These tests can identify the presence of bacteria and even antibiotic resistance genes. Point-of-Care Testing (POCT) devices have gained popularity as they offer rapid results, allowing healthcare providers to initiate treatment more promptly.

Growing Private and Public Sector Investments is Driving the Global Urinary Tract Infection Testing Market

Private sector investments have been a driving force behind the growth of the global UTI testing market. Pharmaceutical and diagnostic companies have recognized the potential for developing innovative solutions to diagnose and manage UTIs more effectively. These investments are directed towards research and development to create advanced diagnostic tests, antibiotics, and therapeutics to treat UTIs. Companies are increasingly focusing on the development of rapid diagnostic tests that offer quicker and more accurate results, enabling healthcare providers to initiate treatment promptly. For instance, the advent of molecular diagnostics and point-of-care testing devices has revolutionized the way UTIs are diagnosed and managed. These innovations offer higher sensitivity and specificity, reducing the chances of misdiagnosis and unnecessary antibiotic prescriptions. Moreover, private sector investments are also supporting the development of alternative therapies, such as novel antibiotics, which can target drug-resistant UTI-causing bacteria. The rise of antibiotic-resistant bacteria is a growing concern, and addressing this issue is crucial to effectively manage UTIs.

Public sector investments, often in the form of research grants, have been instrumental in fostering academic and government research initiatives aimed at improving UTI diagnosis and treatment. Public health organizations and governmental bodies recognize the economic and public health burden that UTIs pose and are actively investing in programs to reduce the prevalence of these infections. Public health campaigns are promoting awareness about UTIs and the importance of timely diagnosis and treatment. Additionally, governments are funding research into the epidemiology and microbiology of UTIs, leading to a better understanding of the causative agents and their drug resistance patterns. Another key aspect of public sector involvement is the development of guidelines and regulations to ensure the responsible use of antibiotics in UTI treatment. Overuse and misuse of antibiotics have contributed to the development of drug-resistant strains, so regulating antibiotic prescribing practices is essential.

The investments made by both the private and public sectors in UTI testing and management are having a global impact. This is particularly important as UTIs are a widespread issue that knows no borders. Access to accurate diagnostics and effective treatments is improving not only in developed nations but also in resource-limited regions, where the burden of UTIs can be especially high.

Key Market Challenges

Overuse of Antibiotics

One of the major challenges facing the UTI testing market is the overuse of antibiotics, which can lead to the development of antibiotic-resistant strains of bacteria. UTIs are often treated empirically, with antibiotics prescribed before the results of a urine culture are available. This overreliance on antibiotics can contribute to the development of antibiotic-resistant bacteria, making treatment less effective in the long run.

Limited Awareness

While UTIs are common, there is a lack of awareness about the importance of proper testing and early diagnosis. Many individuals may self-diagnose and self-medicate without seeking professional medical advice. This limited awareness can lead to delayed diagnosis and treatment, resulting in more severe infections and complications.

False Positives and Negatives

Urinary tract infection testing methods, including dipstick tests and urinalysis, can yield false positives and false negatives. False positives may lead to unnecessary antibiotic treatment, contributing to antibiotic resistance. On the other hand, false negatives can result in missed diagnoses, leading to untreated infections that can worsen over time. Improving the accuracy of UTI testing methods is a critical challenge for the industry.

Lack of Standardization

The lack of standardized UTI testing procedures is another significant challenge. Different laboratories and healthcare facilities may use varying methods and interpret results differently, making it challenging to ensure consistency in UTI diagnosis. Standardization is crucial to ensure the accuracy and reliability of test results.

Cost Constraints

Cost constraints are a substantial challenge for both patients and healthcare providers. Comprehensive UTI testing, including urine culture and sensitivity testing, can be expensive. In resource-limited settings, cost can be a barrier to proper testing, leading to inadequate diagnosis and treatment.

Emerging Technologies

While new technologies are being developed to improve UTI testing, their adoption can be slow and face resistance from traditional testing methods. Healthcare providers may be hesitant to invest in new technologies due to the cost and the need for staff training. The transition from conventional methods to more advanced and accurate testing technologies is a challenge for industry.

Regulatory Hurdles

The global UTI testing market is subject to various regulatory hurdles, with different countries and regions having their own standards and requirements for diagnostic tests. Meeting these regulatory standards can be time-consuming and costly for manufacturers, hindering the availability of advanced testing methods in some areas.

Telemedicine and Remote Testing

The rise of telemedicine and remote testing options presents both opportunities and challenges. While these technologies can improve access to testing, they also raise concerns about the accuracy of remote testing and the potential for misdiagnosis. Ensuring that remote testing methods are accurate and reliable is a challenge that the industry must address.

Key Market Trends

Technological Advancements

Urinary tract infections (UTIs) are one of the most common bacterial infections affecting people of all ages. They can cause discomfort, pain, and even severe health complications if left untreated. The global urinary tract infection testing market has been evolving rapidly in recent years, thanks to the convergence of medical technology and innovative solutions. This market's growth is significantly driven by advancements in technology that have revolutionized the way UTIs are diagnosed, monitored, and treated.

The development of rapid point-of-care testing for UTIs has been a game-changer in healthcare. These tests are cost-effective, non-invasive, and deliver quick results, allowing for immediate diagnosis and treatment. Such technology often relies on innovative lab-on-a-chip devices, automated urinalysis equipment, and smartphone applications. Patients can now test for UTIs at home or at a clinic, leading to quicker interventions and better patient outcomes. Molecular diagnostic techniques, including polymerase chain reaction (PCR) and nucleic acid amplification, have significantly improved the accuracy and reliability of UTI testing. These methods can identify the specific strain of bacteria causing the infection, enabling healthcare providers to prescribe targeted antibiotics. Molecular diagnostics have also reduced the need for culture-based tests, which can take days to yield results.

The integration of digital health solutions, such as telemedicine and electronic health records, has streamlined the UTI testing process. Patients can consult with healthcare professionals remotely, receive electronic prescriptions, and monitor their condition through smartphone apps. These innovations improve the overall patient experience and reduce the burden on healthcare facilities. Artificial intelligence (AI) and machine learning (ML) algorithms are being used to analyze large datasets of UTI patient information. These technologies can assist healthcare professionals in diagnosing and predicting UTIs more accurately. They also help in the development of personalized treatment plans based on a patient's medical history and specific risk factors. The rise of wearable health devices, including smartwatches and fitness trackers, has also contributed to the growth of the UTI testing market. Some of these devices can monitor vital signs and urinary parameters, providing valuable data that can aid in the early detection of UTIs and prompt intervention.

Segmental Insights

Type Insights

Based on the category of type, Cystitis emerged as the dominant in the global market for Urinary Tract Infection Testing in 2024. Cystitis, often referred to as a lower UTI, is an infection or inflammation of the bladder. It is commonly caused by bacteria, such as Escherichia coli (E. coli), which can enter the bladder and lead to various symptoms, including frequent and painful urination, a strong urge to urinate, and discomfort in the pelvic region. Cystitis can affect individuals of all ages and genders, but it is more prevalent in women due to their shorter urethras, which make it easier for bacteria to reach the bladder. Accurate and timely diagnosis of cystitis is crucial for effective treatment and the prevention of complications. As a result, the global urinary tract infection testing market has seen a significant shift towards tests and diagnostic tools specifically designed to detect cystitis. Urine culture tests are among the most common methods for diagnosing cystitis. They involve growing and identifying bacteria in a urine sample to determine the cause of the infection. These tests not only confirm the presence of cystitis but also help in identifying the specific bacteria responsible, aiding in the selection of appropriate antibiotics. Rapid diagnostic tests are becoming increasingly popular as they provide quick results, often within minutes. These tests can detect specific proteins or DNA related to cystitis-causing bacteria. Their speed and accuracy are invaluable in clinical settings, allowing for prompt treatment and reducing the risk of complications.

Regional Insights

North America emerged as the dominant in the global Urinary Tract Infection Testing market in 2024, holding the largest market share in terms of value. North America, including the United States and Canada, has consistently reported a high prevalence of urinary tract infections. UTIs are one of the most common bacterial infections in the region, affecting millions of individuals every year. The prevalence of UTIs is driven by various factors, including lifestyle, diet, and healthcare infrastructure. The higher incidence of UTIs has led to a greater demand for UTI testing services. North America boasts some of the most advanced healthcare systems in the world. With well-established hospitals, clinics, and laboratories, the region has the infrastructure to support sophisticated diagnostic testing procedures. Patients have access to a wide range of healthcare services, including UTI testing, which contributes to the high demand for these tests.

Key Market Players

  • QIAGEN NV
  • Accelerate Diagnostics, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Siemens Healthcare GmbH
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.
  • BIOMERIEUX
  • T2 Biosystems, Inc.

Report Scope:

In this report, the Global Urinary Tract Infection Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Urinary Tract Infection Testing Market, By Type:

  • Urethritis
  • Cystitis
  • Pyelonephritis

Urinary Tract Infection Testing Market, By End use:

  • Urologists
  • Urogynecologists
  • Hospital Laboratories
  • Reference Laboratories
  • Others

Urinary Tract Infection Testing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Urinary Tract Infection Testing Market.

Available Customizations:

Global Urinary Tract Infection Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Urinary Tract Infection Testing Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (Urethritis, Cystitis, Pyelonephritis)
    • 4.2.2. By End use (General Practitioners (GPs), Urologists, Urogynecologists, Hospital Laboratories, Reference Laboratories, Others)
    • 4.2.3. By Region
    • 4.2.4. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Type
    • 4.3.2. By End use
    • 4.3.3. By Region

5. Asia Pacific Urinary Tract Infection Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By End use
    • 5.2.3. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Urinary Tract Infection Testing Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By End use
    • 5.3.2. India Urinary Tract Infection Testing Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By End use
    • 5.3.3. Australia Urinary Tract Infection Testing Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By End use
    • 5.3.4. Japan Urinary Tract Infection Testing Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By End use
    • 5.3.5. South Korea Urinary Tract Infection Testing Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By End use

6. Europe Urinary Tract Infection Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End use
    • 6.2.3. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Urinary Tract Infection Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End use
    • 6.3.2. Germany Urinary Tract Infection Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End use
    • 6.3.3. Spain Urinary Tract Infection Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End use
    • 6.3.4. Italy Urinary Tract Infection Testing Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By End use
    • 6.3.5. United Kingdom Urinary Tract Infection Testing Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By End use

7. North America Urinary Tract Infection Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End use
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Urinary Tract Infection Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End use
    • 7.3.2. Mexico Urinary Tract Infection Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End use
    • 7.3.3. Canada Urinary Tract Infection Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End use

8. South America Urinary Tract Infection Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End use
    • 8.2.3. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Urinary Tract Infection Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End use
    • 8.3.2. Argentina Urinary Tract Infection Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End use
    • 8.3.3. Colombia Urinary Tract Infection Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End use

9. Middle East and Africa Urinary Tract Infection Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End use
    • 9.2.3. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Urinary Tract Infection Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End use
    • 9.3.2. Saudi Arabia Urinary Tract Infection Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End use
    • 9.3.3. UAE Urinary Tract Infection Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End use

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Urinary Tract Infection Testing Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. QIAGEN NV
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Accelerate Diagnostics, Inc.
  • 14.3. Bio-Rad Laboratories, Inc.
  • 14.4. F. Hoffmann-La Roche Ltd.
  • 14.5. Danaher Corporation
  • 14.6. Siemens Healthcare GmbH
  • 14.7. Randox Laboratories Ltd.
  • 14.8. Thermo Fisher Scientific, Inc.
  • 14.9. BIOMERIEUX
  • 14.10.T2 Biosystems, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제